このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Brain Monitors to Reduce Child Confusion After Anesthesia

2026年9月15日 更新者:Baskent University

The Role of BIS-Guided Anesthesia in Reducing Emergence Delirium in Children (Çocuklarda Derlenme Deliryumunun Azaltılmasında BİS Kılavuzluğunda Anestezi)

The goal of this clinical trial was to learn if using a brain monitor to adjust anesthesia (sleep medicine) during surgery could prevent emergence delirium (severe confusion and agitation upon waking) in children aged 2 to 12 years having their tonsils or adenoids removed. The main questions it aimed to answer were:

Did using a brain monitor lower the chance of children waking up confused and upset?

Did using the brain monitor reduce the amount of anesthesia gas (sevoflurane) needed during surgery, and did it affect recovery time or pain levels?

Researchers compared anesthesia adjusted using a bispectral index (BIS) brain monitor to anesthesia adjusted using standard care to see if the brain monitor lowered the chance of emergence delirium.

Participants in the study:

Received general anesthesia (a standardized mix of inhaled and intravenous medicines, including sevoflurane and fentanyl) to safely sleep through surgery to remove their tonsils or adenoids

Had the dose of their main anesthesia gas (sevoflurane) adjusted during surgery based on either brain monitor readings (targeting a specific sleep depth of 40-60) or standard physical responses (like heart rate and blood pressure)

Were checked by the research team immediately after waking up to measure their confusion, agitation, and pain using standard clinical rating scales

調査の概要

詳細な説明

Emergence delirium (ED) represents a significant neurobehavioral complication that frequently occurs during the immediate postoperative period in pediatric populations, particularly following otorhinolaryngological procedures such as adenoidectomy and tonsillectomy. Characterized by severe agitation, altered awareness, disturbed psychomotor behavior, and inconsolability, ED poses safety risks to the recovering patient and increases the burden on healthcare providers and caregivers. While the etiology of ED is multifactorial, the intraoperative depth of anesthesia and the cumulative exposure to specific volatile anesthetics, such as sevoflurane, are known modifiable risk factors. Both excessively deep and inadequately light anesthesia can contribute to poor recovery profiles. The Bispectral Index (BIS) is an electroencephalogram (EEG)-based monitor that provides an objective measurement of a patient's level of consciousness, allowing anesthesiologists to precisely titrate anesthetic agents to an optimal depth.

This prospective, randomized controlled study was designed to investigate the role of BIS-guided anesthetic titration in mitigating the risk of ED. Upon enrollment, pediatric patients undergoing adenoidectomy and/or tonsillectomy were randomized into one of two clinical care pathways: a BIS-guided anesthesia group or a standard-care group.

To ensure baseline consistency across the study, all participants followed a standardized anesthetic induction protocol. Following routine premedication, general anesthesia was induced using inhaled sevoflurane combined with intravenous lidocaine, rocuronium (for muscle relaxation), and fentanyl (for analgesia). For the maintenance phase of anesthesia, patients in both arms received a combination of inhaled sevoflurane and continuous remifentanil infusions.

The critical divergence in the study protocol occurred during the intraoperative maintenance phase:

BIS-Guided Pathway: Anesthesiologists continuously monitored the patient's EEG activity using the BIS monitor. The concentration of the sevoflurane gas was deliberately titrated to maintain a BIS value between 40 and 60, which represents an optimal and safe depth for surgical anesthesia. By keeping patients within this precise target range, the protocol systematically avoided periods of excessively deep (BIS < 40) or overly light (BIS > 60) anesthesia.

Standard-Care Pathway: Anesthesiologists adjusted the sevoflurane concentrations based entirely on traditional clinical signs and autonomic responses, specifically monitoring hemodynamic fluctuations such as heart rate and blood pressure, without the use of EEG-guided depth parameters.

Following the completion of the surgical procedure, patients were transferred to the post-anesthesia care unit (PACU) for close observation. The clinical team systematically evaluated the patients' transition from unconsciousness to wakefulness. To ensure a robust, multi-faceted assessment of neurobehavioral status, the clinical staff utilized three validated behavioral assessment tools: the Pediatric Anesthesia Emergence Delirium (PAED) scale, the Watcha scale, and the Cravero scale. Simultaneously, postoperative physical pain was managed and tracked using the Face, Legs, Activity, Cry, Consolability (FLACC) behavioral scale.

If a patient exhibited signs meeting predetermined thresholds for severe emergence delirium (specifically, a PAED score of 10 or higher, a Watcha score of 3 to 4, or a Cravero score of 4 or higher), the clinical protocol dictated the administration of intravenous fentanyl as a rescue pharmacological intervention to safely manage the agitation.

Through this methodology, the study sought to define the relationship between strict, brain-monitored anesthetic titration and postoperative behavior. It comprehensively evaluated how preventing fluctuations in anesthetic depth impacts overall volatile anesthetic consumption, the necessity for rescue opioids in the recovery room, and the overall quality and speed of pediatric recovery following airway surgery.

研究の種類

介入

入学 (実際)

125

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Children between the ages of 2 and 12 years
  • Scheduled for a planned surgery to remove adenoids, tonsils, or both
  • Generally healthy or having only mild medical conditions (American Society of Anesthesiologists class I or II)
  • Expected to have a surgery that lasts less than 4 hours
  • Having the procedure as an outpatient and expected to go home the same day

Exclusion Criteria:

  • Having severe medical conditions (American Society of Anesthesiologists class III or IV)
  • Having a known history of neurological or psychiatric diseases
  • Diagnosed with a developmental delay
  • Having severe heart, lung, or metabolic conditions
  • Having a known allergy to any of the medications used in the study
  • Parents or legal guardians refuse to provide written consent to participate

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:BIS-Guided Anesthesia
This group received the specific intervention (the BIS monitor to guide anesthesia depth) that is the main focus of your research study.
Anesthetic depth was continuously guided by the Bispectral Index (BIS) monitor. A single-use BIS sensor was placed on the patient's forehead before anesthesia induction to record real-time EEG activity. The primary inhaled anesthetic (sevoflurane) was continuously titrated throughout the surgery to strictly maintain a BIS value within the target range of 40 to 60. If the BIS value dropped below 40, the sevoflurane concentration was decreased. If the BIS value exceeded 60, the continuous remifentanil infusion (0.02-0.1 mcg/kg/min) was increased first, followed by an increase in sevoflurane if necessary. Intervention
アクティブコンパレータ:Standard Care Anesthesia
This group received the standard, established method of care (titrating anesthesia based on heart rate and blood pressure).
Anesthetic depth was guided solely by traditional clinical signs and autonomic responses. The primary inhaled anesthetic (sevoflurane) was initiated at a 1% end-tidal concentration and adjusted in 0.25% increments (range 0.50% to 1.5%) to maintain the patient's heart rate and blood pressure within ±25% of their baseline pre-anesthesia values. Remifentanil was also infused continuously (0.02-0.1 mcg/kg/min) and adjusted based on clinical requirements. A BIS sensor was attached to the patient to record data, but the monitor screen was completely blinded to the anesthesia care provider, ensuring titration relied exclusively on standard hemodynamic metrics.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Primary Outcome Measure 1: Incidence of Emergence Delirium Assessed by the PAED Scale
時間枠:Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Evaluated postoperatively using the Pediatric Anesthesia Emergence Delirium (PAED) scale. The scale ranges from a minimum of 0 to a maximum of 20. Higher scores mean a worse outcome (more severe delirium). Scores of 10 or higher were classified as a positive diagnosis for emergence delirium.
Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Primary Outcome Measure 2: Incidence of Emergence Delirium Assessed by the Watcha Scale
時間枠:Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Evaluated postoperatively using the Watcha behavioral scale. The scale ranges from a minimum of 1 to a maximum of 4. Higher scores mean a worse outcome (greater agitation and delirium). Scores of 3 to 4 were classified as a positive diagnosis for emergence delirium.
Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Primary Outcome Measure 3: Incidence of Emergence Delirium Assessed by the Cravero Scale
時間枠:Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Evaluated postoperatively using the Cravero behavioral scale. The scale ranges from a minimum of 1 to a maximum of 5. Higher scores mean a worse outcome (greater agitation). Scores of 4 or higher were classified as a positive diagnosis for emergence delirium.
Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.

二次結果の測定

結果測定
メジャーの説明
時間枠
Total Sevoflurane Consumption
時間枠:Intraoperative (From anesthesia induction until the completion of surgery).
The total volume of sevoflurane anesthetic gas consumed during the surgical procedure was measured in milliliters (mL).
Intraoperative (From anesthesia induction until the completion of surgery).
Postoperative Pain Assessed by the FLACC Scale
時間枠:Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) behavioral scale. The scale ranges from a minimum of 0 to a maximum of 10. Higher scores mean a worse outcome (more severe pain). Scores of 4 or higher indicated the presence of pain.
Postoperative minutes 5, 10, 15, 30, 45, and 60 following extubation.
Rescue Opioid Usage
時間枠:Up to 60 minutes during the post-anesthesia recovery period.
Administration of intravenous rescue fentanyl (administered at a dose of 1-2 mcg/kg) as an intervention for severe emergence delirium or inadequate pain control.
Up to 60 minutes during the post-anesthesia recovery period.
Recovery Time
時間枠:Up to 4 hours (From transfer to the recovery unit until discharge criteria were successfully met).
Time required to meet safe discharge criteria from the post-anesthesia care unit, determined by the Modified Aldrete Score. The scale ranges from 0 to 10; higher scores mean a better outcome. A score of 9 or higher indicates readiness for discharge.
Up to 4 hours (From transfer to the recovery unit until discharge criteria were successfully met).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年8月8日

一次修了 (実際)

2025年11月21日

研究の完了 (実際)

2025年11月21日

試験登録日

最初に提出

2026年8月4日

QC基準を満たした最初の提出物

2026年9月15日

最初の投稿 (実際)

2026年9月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月17日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する